


## HIV-1 protease-IN-6

<b>Cat. No.:</b>	HY-150549
<b>CAS No.:</b>	2892016-32-7
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>31</sub> FN <sub>2</sub> O <sub>6</sub> S
<b>Molecular Weight:</b>	530.61
<b>Target:</b>	HIV Protease; HIV
<b>Pathway:</b>	Anti-infection; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor, with an IC <sub>50</sub> of 21 pM and a K <sub>i</sub> of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild type virus <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	HIV-1
<b>In Vitro</b>	HIV-1 protease-IN-6 (compound 17d) (10 μM; 48 h) exhibits full inhibition against the late stage of HIV-1 replication cycle while the inhibition rate is 2.6% on early stage at the cellular level <sup>[1]</sup> . HIV-1 protease-IN-6 (10 μM; 24 h) displays antiviral activity against HIV-1NL4-3 with an EC <sub>50</sub> value of 0.74 μM, and exhibits anti-DRV-resistant tendency with an EC <sub>50</sub> value of 0.61 μM towards DRV-resistant variant <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Hu S, et al. A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants. *Bioorg Med Chem*. 2022 Jun 15. 64:116760.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA